Crossmark

Analytical validation of the Percepta genomic sequencing classifier; an RNA next generation sequencing assay for the assessment of Lung Cancer risk of suspicious pulmonary nodules

Crossref DOI link: https://doi.org/10.1186/s12885-021-08130-x

Published Online: 2021-04-13

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Johnson, Marla K.

Wu, Shuyang

Pankratz, Daniel G.

Fedorowicz, Grazyna

Anderson, Jessica

Ding, Jie

Wong, Mei

Cao, Manqiu

Babiarz, Joshua

Lofaro, Lori

Walsh, P. Sean

Kennedy, Giulia C.

Huang, Jing https://orcid.org/0000-0001-8429-0815
License Information

Text and Data Mining valid from 2021-04-13

Version of Record valid from 2021-04-13
More Information

Article History

Received: 8 October 2020

Accepted: 30 March 2021

First Online: 13 April 2021

Declarations

:

: The Percepta Registry and AEGIS cohorts were multi-center prospective studies that included patients with lung nodules who underwent clinically indicated diagnostic bronchoscopy at participating medical centers across the US, Canada and Europe. Ethics review and approval (IRB/REB/IEC) was obtained by each institution before enrollment and informed consent was obtained from all patients. A list of the committee names and approval numbers for each AEGIS-1, AEGIS-2, and Percepta BGC Registry site are included as Supplemental Table 3. All freshly collected blood samples were collected with IRB approval obtained from Liberty IRB (#10.12.0009) and written informed consent from all participants.

: Not applicable.

: All authors are employed by Veracyte Inc.

Document is current

Any future updates will be listed below